Boundless Bio Inc. (BOLD) AI Stock Analysis

• Market Cap: $28.21M
• Dividend Yield: N/A
• Average Volume (3M): 178.65K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.89
• Revenue Growth: N/A
• EPS Growth: -0.50%
• Country: US
• Employees: 64
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.62
• Shares Outstanding: 22,385,610
• 10 Day Avg. Volume: 162,533
• 30 Day Avg. Volume: 178,649
• PEG Ratio: -0.01
• Price to Book (P/B): 0.33
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.78
• Enterprise Value/Market Cap: -1.43
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 64.24
• Enterprise Value/Ebitda: 0.63
• 1Y Price Target: $4.00
• Price Target Upside: 220.00% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -2.59
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $1.00 ▼(-20.00% Downside)

The score is held down primarily by weak financial performance driven by a pre-revenue model, large ongoing losses, and continued cash burn that implies ongoing funding needs. Technical indicators are roughly neutral and provide only modest support, while valuation is constrained by negative earnings and no stated dividend yield.

Positive Factors

Innovative Pipeline

Boundless Bio's focus on ecDNA biology for cancer therapeutics positions it at the forefront of innovative oncology treatments, potentially leading to breakthrough therapies and a strong competitive edge in the biotechnology sector.

Cash Position

A robust cash position provides Boundless Bio with the financial flexibility to continue its R&D activities and sustain operations without immediate external funding, supporting long-term strategic initiatives.

Clinical Trial Progress

Progress in clinical trials, such as the POTENTIATE trial, indicates advancement in drug development, which is crucial for future commercialization and potential revenue streams, enhancing the company's growth prospects.

Negative Factors

Pre-Revenue Model

Operating as a pre-revenue company, Boundless Bio faces significant financial risk as it relies on external funding and successful product development to achieve profitability, which may impact long-term sustainability.

Ongoing Losses

Persistent losses highlight the challenge of covering operating expenses without revenue, which could strain resources and necessitate further funding rounds, potentially diluting shareholder value.

Cash Burn

High cash burn rates indicate that the company is consuming cash rapidly, which may limit its ability to invest in growth opportunities and necessitate additional capital raises, affecting long-term financial health.

Boundless Bio Inc. Business Overview & Revenue Model

Company Description

Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California.

How the Company Makes Money

Boundless Bio Inc. generates revenue primarily through the development and commercialization of its proprietary therapies targeting ecDNA in cancer cells. The company may receive funding through partnerships, collaborations, and licensing agreements with other pharmaceutical companies, which provide financial support for its research and development activities. Additionally, revenue could be derived from milestone payments and royalties related to the successful advancement and commercialization of its therapeutic products. Public and private funding rounds may also contribute to its financial resources, enabling ongoing research and clinical trials.

Boundless Bio Inc. Financial Statement Overview

Summary

Boundless Bio Inc. is facing significant financial challenges typical of a biotechnology start-up, with no revenue and high operational costs leading to continued losses. While there are improvements in equity and liquidity, the company heavily relies on external financing for operations. Future stability depends on successful product commercialization and operational efficiency improvements.

Income Statement

Boundless Bio Inc. has consistently reported zero revenue over the past years, indicating no sales or commercialized products. The net income has been negative, showing persistent losses, with net losses increasing year-over-year. The negative EBIT and EBITDA margins further highlight operational challenges and high costs relative to non-existent revenues.

Balance Sheet

The company has shown improvement in its equity position, moving from negative equity to a positive equity situation, which indicates better financial stability. However, the debt-to-equity ratio improvement is due to increasing equity rather than reducing liabilities. The company's cash and short-term investments have increased, providing liquidity, but liabilities remain substantial.

Cash Flow

Operating cash flow remains negative, reflecting the company's inability to generate cash from its core operations. The free cash flow is also negative, indicating that the company is not generating enough cash to cover its capital expenditures. However, significant financing activities suggest reliance on external funding to sustain operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2018
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-627.00K	-1.09M	0.00	0.00	0.00	0.00
EBITDA	-63.93M	-64.28M	-53.84M	-45.53M	-24.62M	-121.36M
Net Income	-61.76M	-65.36M	-49.43M	-45.90M	-25.21M	-128.82M
Balance Sheet
Total Assets	168.72M	206.41M	129.89M	76.83M	113.72M	472.56M
Cash, Cash Equivalents and Short-Term Investments	117.57M	152.11M	120.75M	66.72M	73.03M	414.31M
Total Debt	49.76M	47.63M	2.19M	5.18M	377.00K	7.07M
Total Liabilities	58.55M	55.77M	256.98M	158.53M	151.91M	29.80M
Stockholders Equity	110.17M	150.64M	-127.08M	-81.70M	-38.19M	442.75M
Cash Flow
Free Cash Flow	-52.70M	-63.38M	-47.49M	-40.66M	-25.28M	-119.59M
Operating Cash Flow	-52.12M	-60.84M	-46.85M	-39.60M	-23.25M	-107.98M
Investing Cash Flow	26.65M	-26.10M	-38.26M	16.13M	-59.28M	-185.05M
Financing Cash Flow	230.00K	89.82M	97.90M	126.00K	105.53M	398.46M

Boundless Bio Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.25
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BOLD, the sentiment is Positive. The current price of 1.25 is above the 20-day moving average (MA) of 1.24, above the 50-day MA of 1.20, and above the 200-day MA of 1.24, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 53.85 is Neutral, neither overbought nor oversold. The STOCH value of 52.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BOLD.

Boundless Bio Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ALXO	48 Neutral	$72.11M	-0.60	-118.95%	―	―	31.98%
CLGN	46 Neutral	$21.24M	-1.54	-92.74%	―	280.77%	32.82%
BOLD	45 Neutral	$28.21M	-0.45	-44.88%	―	―	-0.50%
BRNS	44 Neutral	$30.82M	-0.39	-62.30%	―	-100.00%	-26.30%
PLUR	42 Neutral	$28.41M	-0.99	―	―	121.74%	24.75%
ALGS	42 Neutral	$55.69M	-0.42	-141.82%	―	-55.88%	6.14%